Capabilities Performance Outcomes
Total Page:16
File Type:pdf, Size:1020Kb
MEDSTAR HEART & VASCULAR INSTITUTE Capabilities Performance Outcomes 2021-2022 MEDSTAR HEART & VASCULAR INSTITUTE Leading the evolution of cardiovascular care. The true hallmarks of a world-class cardiovascular program are having Stats at a glance extraordinary breadth and depth of knowledge extending across intersecting specialties, strengthened by an organization that supports those efforts resulting in superior clinical outcomes. I am pleased to present this MedStar Heart & Table of Contents <1% Vascular Institute Capabilities Performance and Outcomes Report, in which 506 2,631 Carotid I believe these attributes are demonstrated in abundance. Structural Heart Disease 4 TAVR procedures PCI procedures revascularization annually annually stroke rates This report displays our continued dedication to increasing understanding of Interventional Cardiology 6 cardiovascular care across the wide geographic region that we serve. No matter the patient’s point of entry, it is our promise that each will receive the same high- Cardiac Surgery 8 quality care. Additionally, our growing understanding of the connectivity between Aortic Disease Management 10 organ systems and disease states demands an approach that facilitates linkages 133 2,210 58 that span traditional specialty lines, and our “systemness” connectivity promotes Vascular Surgery 12 MitraClip Cardiac surgery Aortic root elective procedures to date procedures annually procedures annually this kind of collaboration. 2 Cardiac Electrophysiology 16 3 There has been no greater test of our system’s personal and professional ability Advanced Heart Failure 20 to adapt than the worldwide coronavirus pandemic. We quickly reinvented the Ventricular Assist Devices (VADs) 22 way we interact with patients and with each other. Virtual patient appointments 198 29 replaced in-person encounters whenever possible. Conferences turned virtual Heart Transplantation 23 172 CABG +AVR Heart almost overnight. A robust digital campus was created for continuing education. Mitral valve procedures transplantations Cardiology and Specialty Programs 24 surgeries annually All of this has been a nearly seamless transition and the experience and creativity annually in 2020 will no doubt have an impact on how we deliver medical care—and continually Cardiovascular Imaging 28 educate ourselves—long after COVID-19 is no longer an immediate threat. Cardiovascular Critical Care 30 A great cardiovascular program is first and foremost built upon a contingent Advanced Practice Providers 31 563 of superior clinicians who interact and collaborate freely with one another. WATCHMAN® 1,637 TOP 5 Our success is the result of a talented multidisciplinary cadre of experts — Cardiac ablations VAD centers Nursing 31 procedures annually in U.S. outstanding leaders in their fields. I am delighted to welcome Abeel Mangi, MD, to date Cardiac Hospitalists 31 as the system chair of Cardiac Surgery. Dr. Mangi comes to us from his position CAPABILITIES PERFORMANCE OUTCOMES CAPABILITIES as professor of surgery and surgical director of the Structural Heart and Cardiac PERFORMANCE OUTCOMES CAPABILITIES Cardiac Anesthesiologists 31 Valve Program at Yale New Haven Health. He takes the helm of a cardiac surgery Research 32 17,900 program that has set the standard in our region for nearly four decades. 175+ Cardiac MRI, CT, 175 Our groundbreaking research enterprise continues to grow exponentially, with Graduate Medical Education 34 Cardiovascular Current research TEE, and TTE physicians studies dozens of clinical trials underway. Likewise, we continue to enrich physician Continuing Medical Education 35 interpretations annually training, including a recent expansion of our highly selective MedStar Georgetown Zirkin Heart & Vascular Hospital 36 University-Washington Hospital Center Cardiovascular Disease Fellowship Program, now one of the largest in the nation. Cleveland Clinic Alliance 36 All that we do is singularly focused on improving the lives of our patients and MedSTAR Transport 36 the well-being of our community at large. I welcome your comments, feedback, Quality and Safety 37 Visit us at MedStarHeartInstitute.org. and participation in our programs. Physician Listing 38 Contact Information 39 MedStar Health Locations Map 39 Throughout this report, we share our best available data. In many cases, due to the consequences of the COVID-19 pandemic, that data is from calendar year 2019. Please submit any comments to [email protected] or [email protected]. Stuart F. Seides, MD Some of the photos in this publication were taken prior to the COVID-19 pandemic. All patients and providers are expected to follow the current MedStar Health Physician Executive Director guidelines for safety including proper masking and physical distancing where appropriate. Learn more at MedStarHealth.org/Safe. MedStar Heart & Vascular Institute MEDSTAR HEALTH | Table of Contents MEDSTAR HEART & VASCULAR INSTITUTE | Message from the Physician Executive Director Right ventricular Patient-centered outflow tract D TAVR process In addition to the clear clinical advantages, our approach to Mitral valve TAVR centers around the patient experience. Through expedited workups, fewer trips to the hospital, F B and dramatically reduced wait times, the entire procedure can Aortic valve be coordinated and conducted on site, and often can be completed Baltimore region team Washington, D.C. region team in under 24 hours. After the A C procedure, many patients are Tricuspid discharged home as early as E valve 4 Structural heart disease one day post-procedure. 5 Drawing from the collective expertise of cardiac surgeons, interventional cardiologists, cardiac imaging specialists, and others, we offer the widest range of treatment options and devices for patients with structural heart disease. Our multidisciplinary team analyzes each case to determine the optimal approach to achieving sustainable results. We manage the most challenging cases and often provide second opinions, as well as alternative options for interventions and devices. Pulmonary valve Transcatheter aortic valve Mitral and tricuspid valve interventions replacement (TAVR) As leaders in aortic valve procedures, we continue to expand options available Comprehensive structural heart options We have pioneered TAVR since its inception in for patients with mitral and tricuspid valvular disease. 2007, serving as a clinical testing site for every A. Aortic valve disease B. Mitral valve disease C. Congenital heart defects • AltaValve™ is a transcatheter mitral valve replacement (TMVR) device that is • SAPIEN S3™ Ultra • Intrepid™ Transcatheter Mitral Valve • ASD occluder advancement thereafter. We remain the largest delivered transeptally. As part of the ongoing, early feasibility study, we are • CoreValve®, Evolut™ PRO+ Replacement (TMVR) system • VSD occluder CAPABILITIES PERFORMANCE OUTCOMES CAPABILITIES program in the region offering TAVR for severe evaluating its use for treatment of moderate-to-severe or severe mitral valve PERFORMANCE OUTCOMES CAPABILITIES • Portico™ (trial) • Mitral Dock • PFO occluder for cryptogenic stroke aortic stenosis and aortic regurgitation. regurgitation in patients considered high risk for open surgery. • MitraClip™ Clinical • JenaValve for stenosis and regurgitation • We are the second highest enroller in the country for the SUMMIT trial, testing the ™ D. Stroke prevention and AFib ™ • Tendyne transcatheter mitral valve ™ trial ™ • ACURATE neo2 Aortic Valve System • WATCHMAN FLX device safety and efficacy of the Tendyne transcatheter mitral valve replacement system replacement (TMVR) system highlights as an alternative to open-heart surgery. Expedited TAVR process • BASILICA • CHAMPION-AF (trial) • ENCIRCLE trial for SAPIEN M3 System • AMPLATZER™ Amulet™ device (trial) • The Intrepid™ TMVR system is a new option for patients with severe, symptomatic Initial referral to procedure Transcatheter mitral valve replacement TAVR mortality Para-valvular leak • PINNACLE FLX (trial) mitral regurgitation, currently under investigation in the APOLLO trial. • Amplatzer™ Vascular Plug via transseptal access in-hospital 506 • SAPIEN S3 for mitral annular • Transcatheter Mitral Cerclage Annuloplasty involves a new technique and E. Dysfunctional RVOT conduit/ <.4% Compared to device that was developed in partnership with the National Institutes of Health. <2 Weeks calcification (MITRAL trial) pulmonary valve ™ ACC Standard .9% TAVR procedures Patients with symptomatic severe mitral valve regurgitation are benefitting from • Novel technique to prevent LVOT • SAPIEN 3 this investigational percutaneous procedure to reduce regurgitation, prevent National average: 7 weeks obstruction-LAMPOON Procedure • Melody® Transcatheter Pulmonary Valve further annular dilation, and diminish symptoms. • AltaValve™ TMVR • In the CLASP IID clinical trial, the Edwards PASCAL™ transcatheter valve repair F. Cerebral protection • Sentinel® system is being evaluated in patients with degenerative mitral regurgitation who are at prohibitive risk for open surgery. • We are using the CorMatrix®, a novel tricuspid valve implanted surgically. • The TRILUMINATE study offers a transcatheter clip repair for patients with moderate-to-severe tricuspid regurgitation. MEDSTAR HEALTH | Structural Heart Disease MEDSTAR HEART & VASCULAR INSTITUTE | Structural Heart Disease Interventional Diagnostic cardiology 7,860 catheterizations physicians Washington, D.C. region MitraClips Lowell F. Satler, MD 133 to date Ron Waksman, MD